Form 4: AVITA Medical Director Receives Equity Compensation
Statement of Changes in Beneficial Ownership
Director Jan Stern Reed received restricted stock units and stock options following shareholder approval.
Summary
- Director Jan Stern Reed was granted 22,214 restricted stock units (RSUs) on January 20, 2026.
- Director Jan Stern Reed was granted 16,133 stock options with an exercise price of $3.77 on January 20, 2026.
- Both equity grants were subject to shareholder approval, which was officially obtained on June 3, 2026.
- The total beneficial ownership for the director following these transactions is 73,225 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Successful receipt of shareholder approval for director compensation packages.
Negatives
- Dilutive impact of new equity grants on existing shareholders.
Risks
- Market price volatility affecting the value of granted options and RSUs.
- Vesting requirements tied to continued service.
Future Outlook
The RSUs are subject to time-based vesting 12 months following the grant date of January 20, 2026, and options become exercisable on January 20, 2027.
Industry Context
StockSavvy.ai notes that equity-based compensation for non-executive directors is a standard corporate governance practice in the medical device sector to ensure board alignment with company performance.
Comparison to Industry Standards
- The use of time-based vesting for director equity is consistent with standard practices for Nasdaq-listed medical technology companies.
- Granting a mix of RSUs and options is a common retention strategy for board members in the healthcare industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Approval of equity grants for non-executive directors. | 06/03/2026 | Standard alignment of board incentives. |
Stakeholder Impact
- Shareholders experience minor dilution from the issuance of new equity.
Next Steps
- Vesting of RSUs on January 20, 2027.
- Options become exercisable on January 20, 2027.
Key Dates
| Date | Description |
|---|---|
| 01/20/2026 | Grant date for RSUs and stock options. |
| 01/20/2027 | Vesting date for stock options. |
| 06/03/2026 | Date of shareholder approval for the equity grants. |
| 06/04/2026 | Filing date of the Form 4. |
| 01/20/2036 | Expiration date for stock options. |
Keywords
AVITA Medical, RCEL, Form 4, Director Compensation, Equity Grant, Insider Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.